LENZ Therapeutics plans to seek FDA approval for its investigational eye drops for presbyopia, setting up the drug to compete against AbbVie’s Vuity and Orasis Pharmaceuticals’ Qlosi.
The biopharma on Wednesday shared positive Phase 3 data for two formulations of the treatment, saying both met the study’s primary endpoint, though it plans to pursue an NDA for the version that doesn’t include brimonidine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.